Shanghai - Delayed Quote CNY

Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS)

Compare
41.50 -1.79 (-4.13%)
At close: November 22 at 3:00 PM GMT+8
Loading Chart for 688091.SS
DELL
  • Previous Close 43.29
  • Open 43.08
  • Bid 41.50 x --
  • Ask 41.51 x --
  • Day's Range 41.50 - 43.63
  • 52 Week Range 20.27 - 54.28
  • Volume 2,649,594
  • Avg. Volume 3,481,573
  • Market Cap (intraday) 8.539B
  • Beta (5Y Monthly) -0.40
  • PE Ratio (TTM) 345.83
  • EPS (TTM) 0.12
  • Earnings Date --
  • Forward Dividend & Yield 0.31 (0.75%)
  • Ex-Dividend Date May 17, 2024
  • 1y Target Est --

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. The company develops paclitaxel polymer micelle for treatment of small cell lung cancer. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is headquartered in Shanghai, China.

www.yizhongpharma.com

304

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688091.SS

View More

Performance Overview: 688091.SS

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

688091.SS
14.79%
SSE Composite Index
9.82%

1-Year Return

688091.SS
2.83%
SSE Composite Index
6.49%

3-Year Return

688091.SS
59.04%
SSE Composite Index
8.23%

5-Year Return

688091.SS
67.79%
SSE Composite Index
11.53%

Compare To: 688091.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688091.SS

View More

Valuation Measures

Annual
As of 11/22/2024
  • Market Cap

    8.54B

  • Enterprise Value

    7.90B

  • Trailing P/E

    333.03

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    39.87

  • Price/Book (mrq)

    5.94

  • Enterprise Value/Revenue

    31.50

  • Enterprise Value/EBITDA

    106.01

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    26.17%

  • Return on Assets (ttm)

    2.03%

  • Return on Equity (ttm)

    4.58%

  • Revenue (ttm)

    250.66M

  • Net Income Avi to Common (ttm)

    65.6M

  • Diluted EPS (ttm)

    0.12

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    654.14M

  • Total Debt/Equity (mrq)

    0.76%

  • Levered Free Cash Flow (ttm)

    23.63M

Research Analysis: 688091.SS

View More

Company Insights: 688091.SS

Research Reports: 688091.SS

View More

People Also Watch